ArticlePediatric transplantation2026
Effect of Pediatric Heart Transplant Waitlist Inactivation on Waitlist and Posttransplant Outcomes.
Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about pediatric heart transplant candidates facing waitlist inactivation. We characterized them and assessed the impact of inactivation on waitlist and transplant outcomes.
methodsThe Organ Procurement and Transplantation Network database was queried for pediatric heart-only transplant candidates. Characteristics, waitlist mortality, and 1-year posttransplant survival between inactivated and non-inactivated patients were compared. Predicted probability for the composite outcome of waitlist mortality or removal due to clinical deterioration over time was computed.
resultsOf 5202 patients, 1716 (33%) were inactivated, mostly due to temporary illness (58%). Reasons for inactivation varied by age but not diagnosis. Inactivated patients had longer waitlist duration (171 [77-391] vs. 62 [21-144], p < 0.001), more congenital heart disease (61.0% vs. 55.2%, p < 0.001), and were more often supported by ventricular assist device (47.9% vs. 32.9%, p < 0.001) and invasive ventilation at listing (19.9% vs. 13.6%, p < 0.001). Inactivated patients were less likely listed Status 1A (56.8% vs. 62.3%, p < 0.001) and less likely under intensive care at transplant (43.9% vs. 50.2%, p < 0.001). Inactivated patients had higher 1-year waitlist mortality and removal due to clinical deterioration (SHR 4.40 [3.72-5.20], p < 0.001), though this risk decreased with longer inactive time. One-year posttransplant survival was similar between groups.
conclusionsWaitlist inactivation was strongly associated with 1-year waitlist mortality and removal due to clinical deterioration. However, this risk decreased with longer inactive time and made no difference in short-term posttransplant survival. Thus, the prognostic implications of inactivation are dynamic and can inform future donor allocation policy development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.